Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity

[1]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[2]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[3]  E. Régulier,et al.  The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer , 2002, Cancer Immunology, Immunotherapy.

[4]  B. Rocha,et al.  A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.

[5]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[6]  J. Bluestone,et al.  Cutting Edge: Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells1 , 2002, The Journal of Immunology.

[7]  P. Selvaraj,et al.  Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. , 2002, Cancer research.

[8]  B. Seliger,et al.  Tuning tumor-specific T-cell activation: a matter of costimulation? , 2002, Trends in immunology.

[9]  M. Kieny,et al.  Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies , 2002, Cancer Gene Therapy.

[10]  A. Dahlin,et al.  Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB , 2002, Nature Medicine.

[11]  B. Seliger,et al.  HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.

[12]  N. Gruel,et al.  Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcγR scFv on cancer cell surface , 2001, Gene Therapy.

[13]  P. Zheng,et al.  On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. , 2001, Cancer research.

[14]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[15]  P. Anton van der Merwe,et al.  The TCR Triggering Puzzle , 2001 .

[16]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[17]  K. Liao,et al.  Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. , 2001, Biotechnology and bioengineering.

[18]  B. Seliger,et al.  Characterization of the Major Histocompatibility Complex Class I Deficiencies in B 16 Melanoma Cells 1 , 2001 .

[19]  P. A. van der Merwe,et al.  The TCR triggering puzzle. , 2001, Immunity.

[20]  H. Flad,et al.  Identification of Distinct Surface-Expressed and Intracellular CXC-Chemokine Receptor 2 Glycoforms in Neutrophils: N-Glycosylation Is Essential for Maintenance of Receptor Surface Expression1 , 2000, The Journal of Immunology.

[21]  J. Kim,et al.  B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity , 2000, Gene Therapy.

[22]  J. Kaplan,et al.  Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  K. Liao,et al.  Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells , 2000, Gene Therapy.

[24]  Michael Loran Dustin,et al.  Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. , 2000, Seminars in immunology.

[25]  N. Restifo,et al.  Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.

[26]  K. Liao,et al.  Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. , 1999, Biotechnology and bioengineering.

[27]  M. Little,et al.  Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. , 1999, Journal of immunology.

[28]  J. Becker,et al.  In situ T cells in melanoma , 1999, Cancer Immunology, Immunotherapy.

[29]  W. Schmidt,et al.  The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. , 1999, Journal of immunology.

[30]  J. Ting,et al.  Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. , 1999, Journal of immunology.

[31]  G. Granger,et al.  Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. , 1997, Journal of immunology.

[32]  W. Tao,et al.  Cell surface expression of a human IgC Fc chimera activates macrophages through Fc receptors , 1998, Nature Biotechnology.

[33]  D. Campana,et al.  IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. , 1998, Blood.

[34]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[35]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[36]  D. Hicklin,et al.  HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. , 1998, Cancer research.

[37]  D. Brewster,et al.  Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.

[38]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[39]  C. Springer,et al.  A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy , 1997, Nature Biotechnology.

[40]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[41]  B. Castner,et al.  Further evidence for a common mechanism for shedding of cell surface proteins , 1997, FEBS letters.

[42]  早川 満.  B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells , 1997 .

[43]  H. P. Fell,et al.  Surface Expression of CD28 Single Chain Fv for Costimulation by Tumor Cells , 1996, Immunological reviews.

[44]  J. Massagué,et al.  Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors (*) , 1996, The Journal of Biological Chemistry.

[45]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[46]  I. Saiki,et al.  Vaccination of tumor cells transfected with the B7‐1 (CD80) gene induces the anti‐metastatic effect and tumor immunity in mice , 1996, International journal of cancer.

[47]  H. Grosse-wilde,et al.  Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. , 1996, Cancer research.

[48]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[49]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[50]  K. Sell,et al.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Benner,et al.  Fc receptor binding of anti‐CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine‐related side effects , 1995, European journal of immunology.

[52]  A. Harris,et al.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.

[53]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[54]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[55]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[56]  Young-Woo Kim,et al.  Immune Enhancers Composed of Polyvalent Binding Sites of Anti-CD3 Antibodies , 1993, Bio/Technology.

[57]  J. Bluestone,et al.  Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. , 1990, Transplantation.

[58]  R. Hughey,et al.  O-linked glycosylation of rat renal gamma-glutamyltranspeptidase adjacent to its membrane anchor domain. , 1989, The Journal of biological chemistry.

[59]  M. Krieger,et al.  Effects of O-linked glycosylation on the cell surface expression and stability of decay-accelerating factor, a glycophospholipid-anchored membrane protein. , 1989, The Journal of biological chemistry.